z-logo
open-access-imgOpen Access
Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes
Author(s) -
Usary Jerry,
Darr David Brian,
Pfefferle Adam D.,
Perou Charles M.
Publication year - 2016
Publication title -
current protocols in pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.893
H-Index - 26
eISSN - 1934-8290
pISSN - 1934-8282
DOI - 10.1002/0471141755.ph1438s72
Subject(s) - breast cancer , disease , cancer , genetically engineered , computational biology , medicine , biology , drug discovery , bioinformatics , cancer research , gene , genetics
Advances in the screening of new therapeutic options have significantly reduced the breast cancer death rate over the last decade. Despite these advances, breast cancer remains the second leading cause of cancer death among women. This is due in part to the complexity of the disease, which is characterized by multiple subtypes that are driven by different genetic mechanisms and that likely arise from different cell types of origin. Because these differences often drive treatment options and outcomes, it is important to select relevant preclinical model systems to study new therapeutic interventions and tumor biology. Described in this unit are the characteristics and applications of validated genetically engineered mouse models (GEMMs) of basal‐like, luminal, and claudin‐low human subtypes of breast cancer. These different subtypes have different clinical outcomes and require different treatment strategies. These GEMMs can be considered faithful surrogates of their human disease counterparts. They represent alternative preclinical tumor models to cell line and patient‐derived xenografts for preclinical drug discovery and tumor biology studies. © 2016 by John Wiley & Sons, Inc.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here